Phase 2RecruitingAge-related condition
Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Oral PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis
- Sponsor
- Contineum Therapeutics (Industry)
- Enrolment
- 324 planned
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- PIPE-791 Dose A; PIPE-791 Dose B; Placebo
- Ages
- adults, older adults
- Registry
- NCT07284459
Full record on ClinicalTrials.gov
From the registry
This is a Ph 2, randomized, double-blind, placebo-controlled global multicenter study to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of PIPE-791 in participants with a diagnosis of Idiopathic Pulmonary Fibrosis (IPF) with or without background treatment.
Primary outcomes
- Absolute change in forced vital capacity (FVC) (mL)
History
Study completion expected
Primary completion expected
Last registry update
Started
Registered